In conclusion, we demonstrated a “safety” scoring of pre-treatment plasma biomarkers (IP-10, IL-22BP, and sCD163) predicting early DILI in patients with culture-confirmed pulmonary TB scheduled for TB medications. The gene discussed is CXCL10; the disease is pulmonary tuberculosis.